<DOC>
	<DOCNO>NCT00886743</DOCNO>
	<brief_summary>This open-label study oprelvekin administer prevention severe low blood platelet cell count ( cell blood keep bleed clot stable ) adult cancer take chemotherapy ( anti-cancer drug ) side effect block bone marrow make platelet cell . The purpose study learn effect recommend dose oprelvekin heart 's electrical cycle .</brief_summary>
	<brief_title>Study Evaluating The Effects Of Oprelvekin On Cardiac Repolarization In Subjects With Chemotherapy Induced Thrombocytopenia</brief_title>
	<detailed_description />
	<mesh_term>Thrombocytopenia</mesh_term>
	<mesh_term>Oprelvekin</mesh_term>
	<criteria>Men woman must 18 65 year age , nonmyeloid malignancy oprelvekin indicate . At least one document occasion adequate hematologic recovery previous current chemotherapy . Adequate renal hepatic excretory function . A marked baseline prolongation QT/QTc interval ( eg , repeat [ two three reading ] demonstration QTcF interval &gt; 450 msec . Additional risk factor torsades de pointes include heart failure ( subject functional class III IV congestive heart failure ) , hypokalemia , hypomagnesemia , hypocalcemia . A pace maker defibrillator . A history LQTS , syncope , seizure , unexplained cardiacrelated death family member le 30 year age . Requirement concomitant prescription nonprescription medication dietary supplement risk cause torsades de pointes prolong QT/QTc interval .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>